Ureter Cancer - Pipeline Review, H2 2016


#862937

103pages

Global Markets Direct

$ 2000

In Stock

Ureter Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ureter Cancer Pipeline Review, H2 2016, provides an overview of the Ureter Cancer (Oncology) pipeline landscape.

Ureter cancer or ureteral cancer is cancer of the ureter. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. Risk factors include smoking. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ureter Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ureter Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ureter Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ureter Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively for Ureter Cancer.

Ureter Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Ureter Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ureter Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ureter Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ureter Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ureter Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ureter Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ureter Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Ureter Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Ureter Cancer - Overview 7
Pipeline Products for Ureter Cancer - Comparative Analysis 8
Ureter Cancer - Therapeutics under Development by Companies 9
Ureter Cancer - Therapeutics under Investigation by Universities/Institutes 10
Ureter Cancer - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Ureter Cancer - Products under Development by Companies 14
Ureter Cancer - Products under Investigation by Universities/Institutes 15
Ureter Cancer - Companies Involved in Therapeutics Development 16
Altor BioScience Corporation 16
Eisai Co., Ltd. 17
Exelixis, Inc. 18
GlaxoSmithKline Plc 19
Merck & Co., Inc. 20
Ureter Cancer - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
ALT-801 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
cabozantinib s-malate - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
eribulin mesylate - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
GSK-3326595 - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
pembrolizumab - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
PGV-001 - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
Appendix 102
Methodology 102
Coverage 102
Secondary Research 102
Primary Research 102
Expert Panel Validation 102
Contact Us 102
Disclaimer 103

List of Tables
Number of Products under Development for Ureter Cancer, H2 2016 7
Number of Products under Development for Ureter Cancer - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Products under Development by Companies, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Ureter Cancer - Pipeline by Altor BioScience Corporation, H2 2016 16
Ureter Cancer - Pipeline by Eisai Co., Ltd., H2 2016 17
Ureter Cancer - Pipeline by Exelixis, Inc., H2 2016 18
Ureter Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016 19
Ureter Cancer - Pipeline by Merck & Co., Inc., H2 2016 20
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Stage and Target, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29

List of Figures
Number of Products under Development for Ureter Cancer, H2 2016 7
Number of Products under Development for Ureter Cancer - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Top 10 Targets, H2 2016 22
Number of Products by Stage and Top 10 Targets, H2 2016 22
Number of Products by Top 10 Mechanism of Actions, H2 2016 24
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 24
Number of Products by Routes of Administration, H2 2016 26
Number of Products by Stage and Routes of Administration, H2 2016 26
Number of Products by Molecule Types, H2 2016 28
Number of Products by Stage and Molecule Types, H2 2016 28